Stock Analysis

Medley And Two More Japanese Exchange Growth Companies With High Insider Ownership

Published

Amid a backdrop of fluctuating global markets, Japanese stocks recently retreated from record highs due to heightened speculation around currency interventions. This shift underscores the complexity and sensitivity of Japan's market dynamics, particularly for export-focused industries. In such an environment, growth companies with high insider ownership in Japan may offer a unique appeal, as significant insider stakes often reflect confidence in the company's long-term prospects amidst market volatility.

Top 10 Growth Companies With High Insider Ownership In Japan

NameInsider OwnershipEarnings Growth
Hottolink (TSE:3680)27%59.7%
Kasumigaseki CapitalLtd (TSE:3498)34.8%42.9%
Medley (TSE:4480)34%28.7%
Micronics Japan (TSE:6871)15.3%39.8%
Kanamic NetworkLTD (TSE:3939)25%28.9%
SHIFT (TSE:3697)35.4%32.5%
ExaWizards (TSE:4259)21.9%91.1%
Money Forward (TSE:3994)21.4%66.9%
Astroscale Holdings (TSE:186A)20.9%90%
Soiken Holdings (TSE:2385)19.8%118.4%

Click here to see the full list of 96 stocks from our Fast Growing Japanese Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

Medley (TSE:4480)

Simply Wall St Growth Rating: ★★★★★★

Overview: Medley, Inc. operates platforms for recruitment and medical businesses in Japan, with a market capitalization of approximately ¥144.54 billion.

Operations: The company generates revenue through its recruitment and medical platform operations in Japan.

Insider Ownership: 34%

Medley, a company in Japan, showcases significant growth potential with its earnings forecasted to increase by 28.7% annually, outpacing the Japanese market's expectation of 9%. Similarly, revenue is expected to grow at 24.9% per year. Despite a highly volatile share price recently, Medley's return on equity is anticipated to reach an impressive 21.9% in three years. Recently, Medley raised its fiscal year guidance significantly due to strong performance expectations and also held a shareholders meeting discussing strategic corporate changes including share consolidation.

TSE:4480 Earnings and Revenue Growth as at Jul 2024

PeptiDream (TSE:4587)

Simply Wall St Growth Rating: ★★★★★☆

Overview: PeptiDream Inc. is a biopharmaceutical company focused on the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics, with a market capitalization of approximately ¥370.55 billion.

Operations: The company generates revenue through its biopharmaceutical activities, focusing on the development of unique therapeutic peptides and small molecule drugs.

Insider Ownership: 26.1%

PeptiDream, a Japanese biotech firm, is seeing robust growth with its proprietary Peptide Discovery Platform System technology. Recently, it expanded a significant collaboration with Novartis and revised its fiscal year earnings upwards, reflecting strong operational performance. Despite high revenue growth forecasts of 10.5% annually outpacing the Japanese market's 4.4%, concerns include a highly volatile share price and lower profit margins compared to last year. Insider ownership remains stable with no substantial buying or selling reported recently.

TSE:4587 Ownership Breakdown as at Jul 2024

BayCurrent Consulting (TSE:6532)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BayCurrent Consulting, Inc. offers consulting services in Japan and has a market capitalization of approximately ¥685.02 billion.

Operations: The firm specializes in consulting services within Japan.

Insider Ownership: 13.9%

BayCurrent Consulting, a consultancy firm in Japan, exhibits notable growth with its recent share buyback of ¥3.6 billion indicating confidence from management. Despite trading 40.5% below estimated fair value and possessing a highly volatile share price, the company forecasts an 18.2% annual revenue growth and an 18.7% increase in earnings per year, outpacing the Japanese market averages of 4.4% and 9%, respectively. However, its growth rates are not exceptionally high compared to some peers in the sector.

TSE:6532 Earnings and Revenue Growth as at Jul 2024

Make It Happen

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're helping make it simple.

Find out whether BayCurrent Consulting is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com